HomeCompareASPHF vs SPHD

ASPHF vs SPHD: Dividend Comparison 2026

ASPHF yields 23.58% · SPHD yields 4.33%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ASPHF wins by $64.2K in total portfolio value
10 years
ASPHF
ASPHF
● Live price
23.58%
Share price
$8.48
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$90.8K
Annual income
$9,716.36
Full ASPHF calculator →
SPHD
SPHD
● Live price
4.33%
Share price
$49.34
Annual div
$2.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$571.32
Full SPHD calculator →

Portfolio growth — ASPHF vs SPHD

📍 ASPHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodASPHFSPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ASPHF + SPHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ASPHF pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ASPHF
Annual income on $10K today (after 15% tax)
$2,004.72/yr
After 10yr DRIP, annual income (after tax)
$8,258.91/yr
SPHD
Annual income on $10K today (after 15% tax)
$367.92/yr
After 10yr DRIP, annual income (after tax)
$485.62/yr
At 15% tax rate, ASPHF beats the other by $7,773.28/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ASPHF + SPHD for your $10,000?

ASPHF: 50%SPHD: 50%
100% SPHD50/50100% ASPHF
Portfolio after 10yr
$58.6K
Annual income
$5,143.84/yr
Blended yield
8.77%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ASPHF buys
0
SPHD buys
0
No recent congressional trades found for ASPHF or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricASPHFSPHD
Forward yield23.58%4.33%
Annual dividend / share$2.00$2.14
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$90.8K$26.5K
Annual income after 10y$9,716.36$571.32
Total dividends collected$55.9K$5.1K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: ASPHF vs SPHD ($10,000, DRIP)

YearASPHF PortfolioASPHF Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$13,058$2,358.49$11,133$432.85+$1.9KASPHF
2$16,851$2,878.35$12,363$450.36+$4.5KASPHF
3$21,502$3,471.29$13,695$467.39+$7.8KASPHF
4$27,147$4,139.59$15,138$483.90+$12.0KASPHF
5$33,931$4,884.42$16,697$499.88+$17.2KASPHF
6$42,012$5,705.77$18,382$515.31+$23.6KASPHF
7$51,555$6,602.47$20,198$530.17+$31.4KASPHF
8$62,737$7,572.20$22,157$544.46+$40.6KASPHF
9$75,740$8,611.61$24,266$558.18+$51.5KASPHF
10$90,758$9,716.36$26,536$571.32+$64.2KASPHF

ASPHF vs SPHD: Complete Analysis 2026

ASPHFStock

Ascentage Pharma Group International, a clinical-stage biotechnology company, engages in developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in the United States and Mainland China. Its primary product HQP1351, a BCR-ABL inhibitor targeting BCR-ABL mutants, including those with the T315I mutation, as well as for patients with tyrosine kinase inhibitor resistant chronic phase chronic myeloid leukemia. It also has APG-2575, an orally administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors, which is under Phase Ib/II clinical study; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interaction for treating solid tumors and hematological malignancies; and APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection. In addition, it is involved in the development of APG-1252, a small molecule drug to restore apoptosis through selective inhibition of the Bcl-2 and Bcl-xL proteins for SCLC, lymphoma, and other solid tumors; APG-2449 for non-small-cell lung carcinoma; APG-5918, an orally available and selective EED inhibitor with a best-in-class potential that is under pre-clinical stage; APG-265, which is in the IND-enabling stage for hematological malignancies and solid tumors; and UBX1967/1325 targeting Bcl family indicated for DME that is under Phase II development. Ascentage Pharma Group International has collaboration relationships with major biotechnology and pharmaceutical companies, and academic institutions, which include Innovent Biologics, Inc.; National Cancer Institute; Pfizer Inc.; and Clover Biopharmaceuticals (Hong Kong) Co., Limited. The company was founded in 2009 and is headquartered in Suzhou, China.

Full ASPHF Calculator →

SPHDETF

The Invesco S&P 500 High Dividend Low Volatility ETF (Fund) is based on the S&P 500 Low Volatility High Dividend Index (Index). The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. Standard & Poor's compiles, maintains and calculates the Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility. The Fund and the Index are rebalanced and reconstituted semi-annually, in January and July.

Full SPHD Calculator →
📬

Get this ASPHF vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ASPHF vs SCHDASPHF vs JEPIASPHF vs OASPHF vs KOASPHF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.